{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:47:54Z","timestamp":1785887274645,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015660","name":"UCB Pharma Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cellimm.2026.105128","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:45:49Z","timestamp":1782542749000},"page":"105128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitro"],"prefix":"10.1016","volume":"426","author":[{"given":"Julija","family":"Sirina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena E.","family":"D'Hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Singhvi-Hanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne L.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Shock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Holliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh A.","family":"Stoddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2026.105128_bb0005","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc receptor \u2013 biology and therapeutics","volume":"392","author":"Bussel","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2026.105128_bb0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal Fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0015","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0810796106","article-title":"Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice","volume":"106","author":"Montoyo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2026.105128_bb0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxg018","article-title":"Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans","volume":"15","author":"Ward","year":"2003","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0025","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1242\/jcs.116327","article-title":"Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway","volume":"126","author":"Gan","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cellimm.2026.105128_bb0030","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.172.4.2021","article-title":"Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn","volume":"172","author":"Ober","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0035","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1091\/mbc.e04-08-0735","article-title":"From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling","volume":"16","author":"Ward","year":"2005","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cellimm.2026.105128_bb0040","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1091\/mbc.e13-04-0174","article-title":"Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules","volume":"24","author":"Weflen","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cellimm.2026.105128_bb0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022616","article-title":"Rab proteins and the compartmentalization of the endosomal system","volume":"6","author":"Wandinger-Ness","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4186308","article-title":"The emerging role of Rab5 in membrane receptor trafficking and signaling pathways","volume":"2020","author":"Yuan","year":"2020","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/j.cellimm.2026.105128_bb0055","doi-asserted-by":"crossref","first-page":"12110","DOI":"10.1074\/jbc.M809277200","article-title":"Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration","volume":"284","author":"Vanlandingham","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2026.105128_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.yexcr.2019.04.010","article-title":"A role for Rab11 in the homeostasis of the endosome-lysosomal pathway","volume":"380","author":"Zulkefli","year":"2019","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cellimm.2026.105128_bb0065","article-title":"Cell surface dynamics and cellular distribution of endogenous FcRn","volume":"12","author":"D'Hooghe","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.cellimm.2026.105128_bb0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1091\/mbc.e07-07-0658","article-title":"Ca2+\u2212dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway","volume":"19","author":"Dickinson","year":"2008","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cellimm.2026.105128_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0198-8859(00)00244-5","article-title":"Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells","volume":"62","author":"Antohe","year":"2001","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0080","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.0700337104","article-title":"Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy","volume":"104","author":"Prabhat","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2026.105128_bb0085","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.cellimm.2026.105128_bb0090","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2026.105128_bb0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","article-title":"Targeting the neonatal Fc receptor in autoimmune diseases: pipeline and progress","volume":"39","author":"Gj\u00f8lberg","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.cellimm.2026.105128_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2300155","article-title":"Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fc\u03b3 receptors and functional impact on immune cells in vitro","volume":"16","author":"Qureshi","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.cellimm.2026.105128_bb0105","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellimm.2026.105128_bb0115","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2026.105128_bb0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Jr Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0130","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/bi052628y","article-title":"Albumin binding to FcRn: distinct from the FcRn-IgG interaction","volume":"45","author":"Chaudhury","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.cellimm.2026.105128_bb0135","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1002\/anie.201404238","article-title":"Bio-reduction of redox-sensitive albumin conjugates in FcRn-expressing cells","volume":"53","author":"Br\u00fclisauer","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.cellimm.2026.105128_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3844\/ajisp.2016.1.9","article-title":"Potential of HMEC-1 line and HUVEC primary culture cells to study the neonatal IgG Fc receptor in vitro","volume":"12","author":"Ortiz-Alegria","year":"2016","journal-title":"Am. J. Immunol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cellimm.2026.105128_bb0150","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1073\/pnas.1408766112","article-title":"Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics","volume":"112","author":"Schoch","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellimm.2026.105128_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/19420862.2017.1389355","article-title":"Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics","volume":"10","author":"Piche-Nicholas","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.cellimm.2026.105128_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103746","article-title":"Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life","volume":"25","author":"Grevys","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.cellimm.2026.105128_bb0165","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4155\/bio-2021-0099","article-title":"A cell-based FcRn-dependent recycling assay for predictive pharmacokinetic assessment of therapeutic antibodies","volume":"13","author":"Liu","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.cellimm.2026.105128_bb0170","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.2000732","article-title":"V region of IgG controls the molecular properties of the binding site for neonatal Fc receptor","volume":"205","author":"Rossini","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0175","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1038\/s41467-022-33764-1","article-title":"The fab region of IgG impairs the internalization pathway of FcRn upon fc engagement","volume":"13","author":"Brinkhaus","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105128_bb0180","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176166","article-title":"Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin","volume":"9","author":"Ma","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.cellimm.2026.105128_bb0185","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1600-0854.2009.00887.x","article-title":"Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery","volume":"10","author":"Gan","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.cellimm.2026.105128_bb0190","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/19420862.2015.1008353","article-title":"The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity","volume":"7","author":"Abdiche","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.cellimm.2026.105128_bb0195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-018-03061-x","article-title":"A human endothelial cell-based recycling assay for screening of FcRn targeted molecules","volume":"9","author":"Grevys","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellimm.2026.105128_bb0200","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1091\/mbc.e03-11-0832","article-title":"Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fc\u03b3-receptor","volume":"15","author":"Claypool","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cellimm.2026.105128_bb0205","first-page":"116","article-title":"Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: translation from preclinical stages to the clinic, CPT: Pharmacometrics","volume":"11","author":"Lledo-Garcia","year":"2022","journal-title":"Syst. Pharmacol."},{"key":"10.1016\/j.cellimm.2026.105128_bb0210","unstructured":"European Medicines Agency, Vyvgart Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf, updated 2026 (accessed 18 May 2026)., updated 2026 (accessed 18 May 2026)."},{"key":"10.1016\/j.cellimm.2026.105128_bb0215","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200359","article-title":"FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity","volume":"217","author":"Hubbard","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2026.105128_bb0220","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fimmu.2014.00408","article-title":"The role of FcRn in antigen presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front. Immunol."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874926000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874926000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:15:06Z","timestamp":1785885306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874926000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S0008874926000687"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2026.105128","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitro","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2026.105128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105128"}}